GENE ONLINE|News &
Opinion
Blog

Biogen’s ALS Drug Fails to Attain Primary Endpoint but Offers Hope With Secondary Outcomes

by Rajaneesh K. Gopinath
Share To
While Biogen is grappling with the slow rollout of its Alzheimer's drug Aduhelm over skepticism, it has now unveiled mixed results for its ALS drug.

On October 17th, Biogen announced that its investigational antisense drug, tofersen (BIIB067), did not meet its primary endpoint of treating amyotrophic lateral sclerosis (ALS) in Phase 3 VALOR study. However, the Cambridge, MA-based company claimed that it observed trends favoring tofersen across multiple secondary and exploratory measures of biologic activity and clinical function.

“The wait for new options has been long and difficult for the ALS community, and we welcome this important research advancement in this difficult to treat disease space,” said Timothy Miller, ALS Center Director at Washington University School of Medicine and Principal Investigator of the study.

GO Prime with only $1.49 now

LATEST
Innovative Cellular Mapping of BRCA-Related Breast Cancer Findings Reveals Novel Therapeutic Targets
2024-03-29
Previewing AACR 2024 With Select Pre-Meeting Highlights
2024-03-28
Roche Delivering on Malaria Screening Solutions for Blood Donation
2024-03-28
Innovating Cancer Treatment: The Role of ADC Technology at Nona Biosciences
2024-03-28
BIO CHINA 2024 Brings Biotech Experts and Industry Elites Together for Innovation
2024-03-27
Galderma’s Strong European IPO Debut
2024-03-26
Markets and Mergers: Boston Scientific and Axonics Shake Hands on Deal
2024-03-25
EVENT
2024-04-06
Biotech Innovation Funding Networking
Los Angeles, USA
Scroll to Top